Download NCIC CTG Abstracts to be presented at

NCIC CTG Abstracts to be presented at:
41st Annual ASCO Meeting May 13th – 17th, 2005, Orlando, Florida
Saturday, May 14th, 2005
Sunday, May 15th, 2005 continued
8:00 - 12:00pm
Lung Cancer I
11:15-11:30am
Head and Neck Cancer
Poster Discussion
Session
Smoking history is more predictive of survival
benefit from erlotinib for patients with non-small
cell lung cancer (NSCLC) than EGFR expression
(BR.21)
Oral Abstract
Presentation
Session
A randomized prospective phase-III study
comparing the acute oral mucositis of morning vs.
afternoon radiotherapy (RT) in patients (pts) with
squamous cell carcinoma of the head and neck
(SCCHN): NCIC-CTG HN.3
Presenter: Georg A Bjarnason, MD
Level 4, 414A
Level 3, 304
Presenter: Gary M Clark, PhD
Abstract No: 7033
Abstract No: LBA5500
1:00 - 1:15pm
Sarcoma
Oral Abstract
Presentation
Session
Clinical benefit of imatinib in patients (pts) with
metastatic gastrointestinal stromal tumors (GIST)
negative for the expression of CD117 in the
S0033 trial (SR.4)
Level 4, Valencia
Room, 415B
Monday, May 16th, 2005
12:45 – 1:00pm
Lung Cancer II
Abstract No: 9010
Oral Abstract
Presentation
Session
2:15 - 2:30pm
Lung Cancer I
Level 2, Hall A2
Phase III study of concurrent chemotherapy and
radiotherapy (CT/RT) vs CT/RT followed by
surgical resection for stage IIIA(pN2) non-small
cell lung cancer (NSCLC): Outcomes update of
North American Intergroup 0139 (RTOG 9309)
Oral Abstract
Presentation
Session
Molecular analysis of the epidermal growth factor
receptor (EGFR) gene and protein expression in
patients treated with erlotinib in National Cancer
Institute of Canada Clinical Trials Group (NCIC
CTG) trial BR.21
Level 2, Hall A2
Presenter: Martin E Blackstein, MD, PhD,
FACP
Presenter: Ming S Tsao, MD
Abstract No: 7007
3:45 - 4:00pm
Lung Cancer I
Oral Abstract
Presentation
Session
Low incidence of pneumonitis on SWOG 0023: A
preliminary analysis of an ongoing phase III trial
of concurrent chemoradiotherapy followed by
consolidation docetaxel and gefitinib/placebo
maintenance in patients with inoperable stage III
non-small cell lung cancer (BR.15)
Level 2, Hall A2
Presenter: Kathy S. Albain, MD
Abstract No: 7014
1:15 – 2:45pm
Breast Cancer
Scientific
Symposium
Advances in Monoclonal Antibody Therapy for
Breast Cancer (MA.24, MAC.3)
Level 2, Hall E2
Presenter: George W. Sledge Jr., MD
2:00 – 2:15pm
Lung Cancer II
Oral Abstract
Presentation
Session
Symptom response in non-small cell lung cancer
(NSCLC) patients (pts) treated with erlotinib:
Quality of life analysis of the NCIC CTG BR.21
trial
Level 2, Hall A2
Presenter: Andrea Bezjak, MD
Abstract No: 7018
Presenter: Karen Kelly, MD
Abstract No: 7058
4:00 - 4:15pm
Plenary Session I
(includes David A.
Karnofsky
Memorial Lecture)
Erlotinib plus gemcitabine compared to
gemcitabine alone in patients with advanced
pancreatic cancer. A phase III trial of the National
Cancer Institute of Canada Clinical Trials Group
[NCIC-CTG]
Level 2, Hall D2
2:15 – 2:30pm
Gynecologic Cancer
Oral Abstract
Presentation
Session
Prognostic value of clinical and molecular markers
in advanced ovarian cancer (AOC): importance of
residual (Rs) disease. Translational study using
tumor specimens from EORTC 55931/NCIC
OV10 Phase III Randomized Clinical Trial (RCT)
Level 4,
Valencia Room,
415B
Presenter: Malcolm Moore, MD
Abstract No: 1
Presenter: John A Green, MD, FRCP
Abstract No: 5005
2:00 – 6:00pm
Breast Cancer
Sunday, May 15th, 2005
General Poster
Session
8:00 – 12:00pm
Level 2, Hall C
Determinants of preferences for starting extended
adjuvant letrozole (L) in postmenopausal women
following five years of tamoxifen
General Poster
Session
Level 2, Hall C
Developmental Therapeutics: Molecular
Therapeutics
A phase I study of a second generation antisense
oligonucleotide to clusterin (OGX-011) in
combination with docetaxel: NCIC CTG IND.154
Presenter: Kim N. Chi, MD, FRCPC
Abstract No: 3085
8:00 – 12:00pm
Tumor Biology and Human Genetics
General Poster
Session
Predicting survival using health-related quality of
life scores in gioblastoma cancers: Findings from
an international phase III randomised controlled
trial (CE.3)
Level 2, Hall C
Presenter: Cynthia Luk, MD
Abstract No: 642
Presenter: Andrew Bottomley, PhD
Abstract No: 9601
Tuesday, May 17th, 2005
8:00 - 12:00pm
Lung Cancer
General Poster
Session
Impact of hemoglobin (Hb) on outcomes of
adjuvant chemotherapy (ACT) with
cisplatin/vinorelbine in patients (pts) with
completely resected non-small cell lung cancer
(NSCLC) in JBR.10
Level 2, Hall C
Presenter: Isabelle Gauthier, PharmD
Abstract No: 7200